Falk Gastro Info 6/2014

Video

 

 

Endosonography with targeted aspiration of the suspicious mass

 

Live endoscopy from the HSK Dr. Horst Schmidt Hospitals in Wiesbaden in collaboration with „Video Journal and Encyclopedia of GI Endoscopy“.

Recording in the context of the Falk Symposium 185 „Interfaces and Controversies in Gastroenterology“ on October 3rd – 4th, 2012.

©2013 Elsevier. All rights reserved. With the friendly assistance of Falk Foundation e.V., Freiburg.

 

Presented by:

Erwin Günther, HSK Dr. Horst-Schmidt-Kliniken Wiesbaden, Germany

 

Summary:

This is the case of a 70-year-old woman with pancreatic cancer who underwent a Whipple procedure. At the time, she had stage pT3N1. Afterwards, she received adjuvant chemotherapy. At a routine follow-up examination, sonography produced a suspicious abdominal finding.

For this reason, an endosonography with repeat visualization and targeted aspiration of the suspicious area was performed.

 

Take home messages:

  • Endosonography allows targeted aspiration of otherwise difficult-to-reach lesions in the abdomen and mediastinum.
  • Depending on the texture of the pathological specimen, a small cylinder of tissue can.

 

Please switch on your loudspeakers!

 

 

Link to Falk Mediacenter:

http://media.falkfoundation.de/index.php?id=20&L=1

 

Link to the video directly:

http://media.drfalkpharma.de/fileadmin/media/130502_EUS_mit_FNP_640_FINAL.mp4

 

 

 

Bowel

 

Text:

Ford AC et al, Am J Gastroenterol. 2013;108(8):1268–76

Meta-analysis of randomized controlled trials: Anti-TNF therapy doubles the risk of opportunistic infections in inflammatory bowel disease patients.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=18858#c25857

 

 

Text:

Panaccione R et al, Aliment Pharmacol Ther. 2013;38(10):1236–47

Prolonged adalimumab therapy maintained clinical remission and response in patients with moderately to severely active Crohn’s disease for up to 4 years.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=18858#c25858

 

Text:

Sands BE et al, Gut. 2013;62(9):1288–94

Granulocyte/monocyte apheresis was well tolerated, but this study did not demonstrate its effectiveness over a sham procedure in inducing clinical remission or response in patients with moderate-to-severe Crohn’s disease.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=18858#c25859

 

 

 

Liver
Biliary Tracts

 

 

Text:

Gordon SC et al, Hepatology. 2013;58(2):505–13

Chronic hepatitis B patients with high viral load (HVL) can achieve HBV DNA negativity with long-term tenofovir disoproxil fumarate treatment, although time to HBV DNA < 400 copies/ml may be longer, relative to patients with non-HVL.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=18858#c25860

 

 

Text:

Kraus MR et al, Hepatology. 2013;58(2):497–504

Successful eradication of hepatitis C virus (HCV) leads to a significant improvement of relevant aspects of attentional and neurocognitive performance, indicating that the neurocognitive impairment caused by chronic HCV infection is potentially reversible.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=18858#c25862

 

 

Text:

Aleman S et al, Clin Infect Dis. 2013;57(2):230–6

The risk for hepatocellular carcinoma, liver decompensation, and death in patients with liver cirrhosis related to hepatitis C virus was markedly reduced after sustained virologic response, but a long-term risk of developing hepatocellular carcinoma remains for up to 8 years.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=18858#c25861

 

 

Oesophagus

Stomach

Duodenum

 

 

Text:

Georgopoulos SD et al, Helicobacter. 2013;18(6):459–67

The 10-days “concomitant” regimen with esomeprazole, amoxicillin, metronidazole and clarithromycin is an effective and safe first-line Helicobacter pylori treatment, in a high clarithromycin resistance area, although dual antibiotic resistance (to metronidazole and clarithromycin) may compromise its effectiveness.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=18858#c25863

 

 

Text:

Tsoi KKF et al, Aliment Pharmacol Ther. 2013;38(7):721–8

Meta-Analysis: Oral proton-pump inhibitors demonstrate a similar effectiveness to intravenous proton-pump inhibitors among patients with peptic ulcer bleeding.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=18858#c25864

 

 

Text:

Barletta JF et al, Mayo Clin Proc. 2013;88(10):1085–90

The duration of proton-pump inhibitor (PPI) therapy is significantly associated with Clostridium difficile infection (CDI). The probability for CDI was higher when PPI use exceeded 2 days in patients without a prior hospital admission and 1 day in patients with a prior admission.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=18858#c25865

 

 

 

 

 

 

 

Pancreas

 

 

Text:

Yaghoobi M et al, Aliment Pharmacol Ther. 2013;38(9):995–1001

Rectal indomethacin used immediately before or after endoscopic retrograde cholangiopancreatography (ERCP) significantly reduces the risk of post-ERCP pancreatitis to half in both low- and high-risk patients, and with both statistically and clinically significant conclusions.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=18858#c25866

 

 

 

 

 

 

Current Falk literature:

 

NEW

The “biliary bicarbonate umbrella”

A cornerstone in the pathogenesis and therapy of chronic cholangiopathies?

Author: S. Hohenester

(6 pages)

U14e

 

 

PDF:

http://www.drfalkpharma.de/fileadmin/media/Falk_Broschueren/Diagnostik_und_Therapie/PDF/U14e_1-2-14.pdf

 

 

Order by email (Please replace text by your email address):

 

mailto:text?subject=FGI%206%2F2014:%20Ordering%20of%20brochure%20U14e&body=Please%20send%20the%20brochure%20to%20the%20following%20address:%0A%0A